Header Logo

Marta Batus

Concepts (147)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sarcoma
9
2023
138
2.590
Why?
Lung Neoplasms
15
2024
484
2.010
Why?
Antineoplastic Agents
8
2016
175
1.860
Why?
Carcinoma, Non-Small-Cell Lung
14
2024
201
1.720
Why?
Soft Tissue Neoplasms
2
2022
55
0.910
Why?
Molecular Targeted Therapy
3
2013
31
0.890
Why?
Metastasectomy
1
2021
7
0.790
Why?
Bone Neoplasms
3
2022
111
0.750
Why?
Antibodies, Monoclonal
4
2016
195
0.740
Why?
Immunotherapy
3
2021
51
0.710
Why?
Antineoplastic Combined Chemotherapy Protocols
6
2019
209
0.670
Why?
Direct-to-Consumer Advertising
1
2016
1
0.540
Why?
Medical Oncology
1
2016
35
0.520
Why?
Chemoradiotherapy
4
2019
58
0.500
Why?
Retrospective Studies
16
2023
3105
0.480
Why?
Prognosis
9
2023
727
0.450
Why?
ErbB Receptors
4
2018
50
0.440
Why?
Melanoma
1
2013
50
0.420
Why?
Neoplasm Staging
11
2024
294
0.370
Why?
Humans
28
2024
25234
0.370
Why?
Survival Rate
5
2021
310
0.300
Why?
Mutation
3
2021
306
0.290
Why?
Carcinoma, Squamous Cell
4
2018
155
0.270
Why?
Neutrophils
2
2023
90
0.240
Why?
Female
17
2024
13876
0.240
Why?
Male
16
2024
13575
0.240
Why?
Body Composition
1
2024
59
0.230
Why?
Drug Resistance, Neoplasm
2
2018
61
0.230
Why?
Neoplasm Recurrence, Local
2
2016
182
0.230
Why?
Middle Aged
12
2024
8145
0.220
Why?
Receptor, IGF Type 1
2
2013
17
0.210
Why?
Quinazolines
2
2012
13
0.200
Why?
Sarcoma, Synovial
1
2022
11
0.200
Why?
High-Throughput Nucleotide Sequencing
1
2021
41
0.190
Why?
Pneumonectomy
1
2021
65
0.190
Why?
Adenocarcinoma
3
2018
115
0.180
Why?
Antineoplastic Agents, Immunological
1
2021
15
0.180
Why?
Lung
1
2021
153
0.180
Why?
Autoantibodies
1
2021
59
0.180
Why?
Treatment Outcome
8
2021
3147
0.170
Why?
Biomarkers, Tumor
1
2021
164
0.170
Why?
Erlotinib Hydrochloride
1
2018
8
0.150
Why?
Aged
11
2024
8433
0.150
Why?
Inflammation Mediators
1
2018
53
0.150
Why?
Survival Analysis
5
2021
233
0.140
Why?
Palliative Care
2
2015
97
0.140
Why?
Adult
7
2022
7091
0.140
Why?
Protein Kinase Inhibitors
2
2018
45
0.130
Why?
Neoplasm Metastasis
2
2013
88
0.120
Why?
Gene Dosage
2
2012
18
0.120
Why?
Biomarkers
1
2018
554
0.120
Why?
Radiotherapy, Conformal
1
2014
14
0.110
Why?
Cancer Vaccines
1
2013
6
0.110
Why?
Angiogenesis Inhibitors
1
2013
13
0.110
Why?
Neoplasms
1
2016
213
0.110
Why?
Follow-Up Studies
5
2018
1622
0.110
Why?
Forecasting
1
2013
85
0.110
Why?
Weight Gain
1
2012
61
0.100
Why?
PTEN Phosphohydrolase
1
2011
6
0.100
Why?
Positron Emission Tomography Computed Tomography
2
2022
27
0.100
Why?
Fluorodeoxyglucose F18
2
2022
35
0.100
Why?
Phosphatidylinositol 3-Kinases
1
2011
43
0.100
Why?
Adolescent
2
2016
1998
0.100
Why?
Young Adult
2
2016
1751
0.100
Why?
Child, Preschool
1
2013
588
0.100
Why?
Body Weight
2
2024
117
0.090
Why?
Gene Amplification
1
2010
18
0.090
Why?
Pyrimidines
1
2010
21
0.090
Why?
Xanthine Dehydrogenase
1
2010
5
0.090
Why?
Rectal Neoplasms
1
2010
11
0.090
Why?
United States
1
2016
1906
0.090
Why?
Lymphocytes
2
2023
51
0.090
Why?
Gastrointestinal Stromal Tumors
1
2010
28
0.090
Why?
Gene Expression Regulation, Neoplastic
1
2010
92
0.090
Why?
Piperazines
1
2010
75
0.080
Why?
Clinical Trials as Topic
1
2010
216
0.080
Why?
Child
1
2013
1232
0.080
Why?
Lymphohistiocytosis, Hemophagocytic
1
2008
9
0.080
Why?
Animals
2
2013
3382
0.080
Why?
Chromosomes, Human, Pair 3
1
2007
5
0.070
Why?
Chromosomes, Human, Pair 10
1
2007
6
0.070
Why?
Chromosomes, Human, Pair 1
1
2007
8
0.070
Why?
Receptor, ErbB-2
1
2007
47
0.070
Why?
Carcinoma, Large Cell
2
2018
11
0.070
Why?
Prospective Studies
2
2023
1596
0.060
Why?
Neoadjuvant Therapy
2
2019
57
0.060
Why?
Kaplan-Meier Estimate
2
2017
154
0.060
Why?
Aged, 80 and over
4
2018
4523
0.060
Why?
Etoposide
2
2015
24
0.060
Why?
Carboplatin
2
2015
22
0.060
Why?
Paclitaxel
2
2015
40
0.060
Why?
Lymphocyte Count
1
2023
17
0.050
Why?
Tumor Microenvironment
1
2023
16
0.050
Why?
Breast Neoplasms
1
2007
341
0.050
Why?
Body Mass Index
1
2024
395
0.050
Why?
Margins of Excision
1
2022
27
0.050
Why?
Time-to-Treatment
1
2022
30
0.050
Why?
Radiopharmaceuticals
1
2022
46
0.050
Why?
Positron-Emission Tomography
1
2022
78
0.050
Why?
B7-H1 Antigen
1
2021
9
0.050
Why?
Programmed Cell Death 1 Receptor
1
2021
14
0.050
Why?
Antigens, Neoplasm
1
2021
36
0.050
Why?
Observer Variation
1
2021
87
0.050
Why?
Cohort Studies
2
2015
1758
0.040
Why?
Patient Selection
1
2021
188
0.040
Why?
Mesna
1
2019
2
0.040
Why?
Ifosfamide
1
2019
12
0.040
Why?
Organ Sparing Treatments
1
2019
6
0.040
Why?
Leg
1
2019
46
0.040
Why?
Doxorubicin
1
2019
51
0.040
Why?
Arm
1
2019
72
0.040
Why?
Tomography, X-Ray Computed
2
2014
686
0.040
Why?
Time Factors
1
2022
1329
0.040
Why?
Proteomics
1
2018
87
0.040
Why?
Leukocyte Count
1
2017
62
0.040
Why?
Bevacizumab
1
2016
17
0.030
Why?
Taxoids
1
2016
8
0.030
Why?
Deoxycytidine
1
2016
19
0.030
Why?
Radiation Pneumonitis
1
2015
2
0.030
Why?
Pemetrexed
1
2015
4
0.030
Why?
Hemoptysis
1
2015
7
0.030
Why?
Esophagitis
1
2015
6
0.030
Why?
Cough
1
2015
9
0.030
Why?
Chest Pain
1
2015
18
0.030
Why?
Chemoradiotherapy, Adjuvant
1
2015
13
0.030
Why?
Radiation Injuries
1
2015
23
0.030
Why?
Dyspnea
1
2015
35
0.030
Why?
Disease-Free Survival
1
2015
152
0.030
Why?
Mobility Limitation
1
2015
92
0.030
Why?
Radiotherapy Dosage
1
2014
89
0.030
Why?
Diet
1
2015
164
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2014
55
0.030
Why?
Class I Phosphatidylinositol 3-Kinases
1
2011
10
0.020
Why?
Activities of Daily Living
1
2015
498
0.020
Why?
Immunohistochemistry
1
2012
300
0.020
Why?
Imatinib Mesylate
1
2010
8
0.020
Why?
Benzamides
1
2010
15
0.020
Why?
Colectomy
1
2010
17
0.020
Why?
Combined Modality Therapy
1
2011
268
0.020
Why?
Quality of Life
1
2015
596
0.020
Why?
Signal Transduction
1
2012
380
0.020
Why?
Biopsy
1
2010
191
0.020
Why?
Smoking
1
2010
165
0.020
Why?
Risk Assessment
1
2011
597
0.020
Why?
Fatal Outcome
1
2008
48
0.020
Why?
Trastuzumab
1
2007
25
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2007
87
0.020
Why?
Batus's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (147)
Explore
_
Co-Authors (17)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_